SCHEMBL2321087

SCHEMBL2321087

CCCCCNC(=O)C(=O)NN

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 8/20 0.56
DPP7 Q9UHL4 2/20 0.53
PLA2G2A P14555 1/20 0.50
CASP2 P42575 1/20 0.50
ZDHHC20 Q5W0Z9 1/20 0.47
ZDHHC2 Q9UIJ5 1/20 0.47
NAAA Q02083 1/20 0.47
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
EPHX2 P34913 1/20 0.46
GNAI3 P08754 1/20 0.46
GNAO1 P09471 1/20 0.46
GNAI1 P63096 1/20 0.46
PLA2G4A P47712 1/20 0.46
RRM1 P23921 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9868236 0.98 EPHX1 (0.59) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL9868895 0.98 EPHX1 (0.59) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL9868852 0.93 EPHX1 (0.50) EPHX1DPP7PLA2G2AKDM4ELMNA
SCHEMBL3257790 0.89 EPHX1 (0.68) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL12203408 0.86 EPHX1 (0.73) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL14656966 0.86 EPHX1 (0.73) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL9060648 0.86 EPHX1 (0.73) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL6859201 0.86 EPHX1 (0.73) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL7642286 0.86 EPHX1 (0.73) EPHX1DPP7PLA2G2ACASP2ZDHHC20
SCHEMBL6854878 0.86 EPHX1 (0.73) EPHX1DPP7PLA2G2ACASP2ZDHHC20

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110207726-A1 Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2011-08-25 US claimed
WO-2009136997-A2 INHIBITORS OF HUMAN CATHEPSIN L, CATHEPSIN B, AND CATHEPSIN S THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-11-12 WO claimed
US-20220387356-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2022-12-08 US disclosed
EP-2914575-B1 PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF UNIV MICHIGAN REGENTS (US) 2020-10-14 EP disclosed
US-20200147007-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE EASTERN MICHIGAN UNIVERSITY 2020-05-14 US disclosed
US-20170291893-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF EASTERN MICHIGAN UNIVERSITY 2017-10-12 US disclosed
US-9718760-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-01 US disclosed
US-20150315178-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-11-05 US disclosed
WO-2014070983-A1 PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-05-08 WO disclosed
US-20110207726-A1 Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2011-08-25 US disclosed
WO-2009136997-A2 INHIBITORS OF HUMAN CATHEPSIN L, CATHEPSIN B, AND CATHEPSIN S THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2009-11-12 WO disclosed
US-5051517-A Reacting a chloroformidine hydrochloride with an oxamohydrazide, forming bonds between carbon and nitrogen and cyclization BAYER AKTIENGESELLSCHAFT (DE) 1991-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207726-A1 Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S CTSB, CTSS, CTSV EPHX1 2522/4885DPP7 191/4885PLA2G2A 2187/4885
US-20170291893-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF SERPINE1, PLAT, SERPINC1 EPHX1 353/4885DPP7 356/4885PLA2G2A 450/4885
US-20150315178-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF SERPINE1, PLAT, SERPINC1 EPHX1 353/4885DPP7 356/4885PLA2G2A 450/4885
US-20220387356-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE SERPINE1, PLAT, SERPINC1 EPHX1 482/4885DPP7 333/4885PLA2G2A 429/4885
US-20200147007-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE SERPINE1, PLAT, SERPINC1 EPHX1 482/4885DPP7 333/4885PLA2G2A 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.